KRAS and neoplasm: For example, Next-generation sequencing (NGS) for concomitant driver mutations was performed on EGFR-mutated tumour samples from erlotinib-treated patients and the result showed that most concomitant mutations (including EGFR/K-RAS) did not impact the response to first-line erlotinib-treatment [174].